Janus Henderson Group
EWTX icon

Janus Henderson Group’s Edgewise Therapeutics EWTX Stock Holding History

Janus Henderson Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$186M Buy
5,915,556
+1,348,706
+30% +$38.9M 0.09% 202
2025
Q4 		$113M Sell
4,566,850
-412,481
-8% -$8.28M 0.05% 263
2025
Q3 		$80.8M Sell
4,979,331
-524,018
-10% -$7.43M 0.04% 313
2025
Q2 		$72.1M Buy
5,503,349
+221,195
+4% +$3.19M 0.04% 322
2025
Q1 		$123M Buy
5,282,154
+298,214
+6% +$7.82M 0.07% 236
2024
Q4 		$133M Buy
4,983,940
+425,421
+9% +$13.5M 0.07% 246
2024
Q3 		$122M Buy
4,558,519
+1,951,220
+75% +$38.8M 0.06% 251
2024
Q2 		$46.9M Buy
2,607,299
+801,987
+44% +$14M 0.03% 392
2024
Q1 		$32.9M Buy
1,805,312
+590,299
+49% +$9.38M 0.02% 462
2023
Q4 		$13.2M Buy
1,215,013
+94,246
+8% +$662K 0.01% 623
2023
Q3 		$6.43M Buy
1,120,767
+540,019
+93% +$3.67M ﹤0.01% 758
2023
Q2 		$4.49M Sell
580,748
-189,051
-25% -$1.59M ﹤0.01% 892
2023
Q1 		$5.13M Sell
769,799
-650,070
-46% -$6.03M ﹤0.01% 863
2022
Q4 		$12.7M Sell
1,419,869
-1,666,143
-54% -$15.6M 0.01% 666
2022
Q3 		$30.4M Buy
3,086,012
+1,476,650
+92% +$14.9M 0.01% 601
2022
Q2 		$12.8M Buy
1,609,362
+176,046
+12% +$1.33M 0.01% 643
2022
Q1 		$13.9M Sell
1,433,316
-93,019
-6% -$1.2M 0.01% 826
2021
Q4 		$23.3M Sell
1,526,335
-205,688
-12% -$3.7M 0.01% 749
2021
Q3 		$27.6M Sell
1,732,023
-57,257
-3% -$1.04M 0.01% 712
2021
Q2 		$36.7M Sell
1,789,280
-351,628
-16% -$9.61M 0.02% 649
2021
Q1 		$65.1M Buy
+2,140,908
New +$69.4M 0.03% 475

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group's EWTX Position: Q1 2026 in Review

Janus Henderson Group increased its Edgewise Therapeutics (EWTX) stake by 30% in Q1 2026, buying an estimated $38.9M and bringing the position to 5,915,556 shares worth $186M. The position accounts for 0.09% of the portfolio, ranked #202.

Janus Henderson Group first reported a position in EWTX in Q1 2021 and has held it in 21 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Janus Henderson Group held 5,915,556 shares of Edgewise Therapeutics worth $186M as of Q1 2026.
  • Janus Henderson Group bought 1,348,706 Edgewise Therapeutics shares in Q1 2026, an estimated $38.9M.
  • Edgewise Therapeutics made up 0.09% of Janus Henderson Group's portfolio in Q1 2026, its #202 holding.
  • Janus Henderson Group first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.